Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-Hydroxy-N-Propargyl-1(R)-Aminoindan is a synthetic small molecule with the chemical formula C12H13NO and a molecular weight of approximately 187.24 g/mol[4][3]. It is structurally related to rasagiline, an MAO-B inhibitor used in Parkinson’s disease, but differs by the presence of a hydroxy group at the 5-position on the indan ring. There is no evidence that this compound has been approved for any indication or entered clinical development; it appears to be an experimental or research compound with no established pharmacological use in humans[1][3]. Its mechanism of action and therapeutic potential are not described in available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-hydroxy-n-propargyl-1(r)-aminoindan.